Digestive Diseases and Sciences

, Volume 59, Issue 8, pp 1688–1697

Molecular Therapies in Hepatocellular Carcinoma: What Can We Target?

Authors

  • Roberto Galuppo
    • Division of Transplantation Surgery, Department of Surgery, College of MedicineUniversity of Kentucky
  • Dinesh Ramaiah
    • Division of Transplantation Surgery, Department of Surgery, College of MedicineUniversity of Kentucky
  • Oscar Moreno Ponte
    • Division of Transplantation Surgery, Department of Surgery, College of MedicineUniversity of Kentucky
    • Division of Transplantation Surgery, Department of Surgery, College of MedicineUniversity of Kentucky
Review

DOI: 10.1007/s10620-014-3058-x

Cite this article as:
Galuppo, R., Ramaiah, D., Ponte, O.M. et al. Dig Dis Sci (2014) 59: 1688. doi:10.1007/s10620-014-3058-x

Abstract

Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.

Keywords

Hepatocellular carcinomaSorafenibRas/Raf/MAPKLiver cancer stem cellsEpidermal growth factor

Copyright information

© Springer Science+Business Media New York 2014